The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2019

Filed:

Apr. 06, 2016
Applicants:

Viktor Veniaminovich Tets, St. Petersburg, RU;

Georgy Viktorovich Tets, St. Petersburg, RU;

Inventors:

Viktor Veniaminovich Tets, St. Petersburg, RU;

Georgy Viktorovich Tets, St. Petersburg, RU;

Konstantin Andreevich Krasnov, St. Petersburg, RU;

Assignee:

Other;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); C07D 491/147 (2006.01); A61P 31/20 (2006.01); A61P 31/18 (2006.01); A61K 31/513 (2006.01); A61K 31/7072 (2006.01);
U.S. Cl.
CPC ...
C07D 491/147 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/7072 (2013.01); A61P 31/18 (2018.01); A61P 31/20 (2018.01); A61K 2300/00 (2013.01);
Abstract

The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido[5',4′:5,6]pyrano[2,3-d]pyrimidine-4-ol derivatives, having antiviral activity. Claimed are a drug with antiviral activity against HIV infection and hepatitis B virus, containing 2-chloro-5-phenyl-5H-pyrimido[5′,4′:5,6]pyrano[2,3-d]pyrimidine-4-ol derivatives of the general formula shown, where: X is selected from the group: H, NO, Hal, OMe; R1 is selected from the group: Cl, OH; and R2 is selected from the group: Cl, SH, OH; and a drug with antiviral activity against HIV infection, containing a 2-chloro-5-phenyl-5H-pyrimido[5′,4′:5,6]pyrano[2,3-d]pyrimidine-4-ol derivative of the general formula shown, where: X is selected from the group: H, NO, Hal, OMe; R1 is selected from the group: Cl, OH; and R2 is selected from the group: Cl, SH, OH in combination with a reverse transcriptase inhibitor selected from Retrovir, or in combination with a protease inhibitor selected from Lopinavir, in an effective amount. The result is an effective drug with antiviral activity.


Find Patent Forward Citations

Loading…